Ownership and insider activity for Canopy Growth Corporation (CGC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products.
Price
| Price | $0.92 |
| Market Cap | $387M |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-24 | Gedeon Christelle | S-Sale | 13,344 | $20K |
| 2026-08-24 | Stewart Thomas Carlton | S-Sale | 2,231 | $3K |
| 2026-06-26 | BAYERN JOSEPH | S-Sale | 3,197 | $3K |
| 2026-06-26 | Yanofsky Theresa | S-Sale | 15,054 | $14K |
| 2026-06-26 | ATKINS M SHAN | S-Sale | 3,197 | $3K |
| 2026-06-26 | Lazzarato David Angelo | S-Sale | 22,674 | $21K |
| 2026-06-17 | ATKINS M SHAN | A-Award | 108,324 | |
| 2026-06-17 | Lazzarato David Angelo | A-Award | 162,485 | |
| 2026-06-17 | BAYERN JOSEPH | A-Award | 108,324 | |
| 2026-06-17 | Yanofsky Theresa | A-Award | 108,324 |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $101.8M | $322.6M | $2.48B | $915.6M | $1.15B | $776.0M | $667.7M | $170.3M | $113.8M | $364.7M |
| Short-term Investments | 0 | 0 | $2.06B | $488.2M | $1.16B | $595.7M | $105.5M | $33.2M | $17.7M | $5.1M |
| Receivables | $5.8M | $21.4M | $107.0M | $63.3M | $67.1M | $86.6M | $68.5M | $51.8M | $52.8M | $36.3M |
| Inventory | $60.7M | $118.0M | $190.1M | $274.8M | $369.5M | $204.5M | $83.2M | $77.3M | $96.4M | $154.1M |
| Total Current Assets | $178.8M | $481.8M | $4.92B | $1.80B | $2.84B | $1.73B | $1.08B | $371.2M | $294.6M | $529.5M |
| Property, Plant & Equipment | $96.3M | $303.7M | $1.10B | $1.07B | $1.07B | $942.8M | $471.3M | $320.1M | $293.5M | $441.4M |
| Goodwill | $241.4M | $314.9M | $1.54B | $1.37B | $1.89B | $1.87B | $85.6M | $43.2M | $46.0M | $77.7M |
| Intangible Assets | $162.3M | $101.5M | $519.6M | $334.7M | $308.2M | $252.7M | $160.8M | $104.1M | $87.2M | $128.9M |
| Total Assets | $677.6M | $1.44B | $8.73B | $4.82B | $6.82B | $5.61B | $2.44B | $1.30B | $917.7M | $1.12B |
| Accounts Payable | $5.7M | $46.2M | $188.9M | $86.7M | $67.3M | $64.3M | $31.8M | $28.7M | $26.1M | $34.8M |
| Short-term Debt | $1.7M | $1.6M | $103.7M | $39.9M | $9.8M | $9.3M | $556.9M | $103.9M | $4.3M | $16.2M |
| Total Current Liabilities | $17.7M | $92.0M | $411.7M | $295.5M | $284.3M | $213.2M | $803.8M | $234.7M | $94.4M | $158.4M |
| Long-term Debt | $8.6M | $6.9M | $842.3M | $315.5M | $1.57B | $1.49B | $750.0M | $493.3M | $299.8M | $217.1M |
| Total Liabilities | $62.9M | $193.6M | $1.49B | $1.18B | $3.20B | $1.98B | $1.68B | $799.8M | $430.5M | $421.1M |
| Retained Earnings | -$21.3M | -$91.6M | -$835.1M | -$3.04B | -$6.07B | -$6.38B | -$9.67B | -$10.33B | -$10.93B | -$11.14B |
| Total Equity | $639.8M | $1.16B | $6.78B | $3.43B | $3.48B | $3.58B | $758.4M | $500.4M | $487.2M | $697.6M |
| Total Debt | $10.3M | $8.4M | $946.0M | $439.7M | $1.72B | $1.64B | $1.41B | $668.0M | $348.4M | $278.7M |
| Net Debt | -$91.5M | -$314.1M | -$3.60B | -$964.1M | -$598.3M | $268.5M | $640.5M | $464.5M | $216.9M | -$92.0M |
| Working Capital | $161.1M | $389.7M | $4.51B | $1.51B | $2.55B | $1.51B | $273.4M | $136.5M | $200.2M | $371.0M |
Financial Health
| Debt / Equity | 0.40 |
| Current Ratio | 3.04 |
Profitability
| Return on Equity | -29.85% |
| Return on Invested Capital | -15.31% |
| Return on Assets | -21.43% |
| Gross Margin | 22.87% |
| Operating Margin | -46.89% |
| Net Margin | -73.95% |
Related companies: ACB · ACRS · BIOA · CABA · DH · IRWD · LFCR
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of CGC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks